The Tumor Necrosis Factor Receptor Superfamily Member 9 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Receptor Superfamily Member 9 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Hematological Disorders, and Undisclosed which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Systemic Lupus Erythematosus, Hematoma, and Unspecified. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Receptor Superfamily Member 9 pipeline targets constitutes close to 131 molecules. Out of which, approximately 126 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 31, 35, 5, 42, and 13 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 2, 1, and 2 molecule.
Tumor Necrosis Factor Receptor Superfamily Member 9 overview
Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities.
For a complete picture of Tumor Necrosis Factor Receptor Superfamily Member 9’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
